Comprehensive functional characterisation of a novel ANO6 variant in a new patient with Scott Syndrome

Samantha Montague, Joshua Price, Katherine Pennycott, Natasha Pavey, Eleyna Slater, Isaac Thirlwell, Sam Kemble, Catarina Monteiro, Lily Redmond-Motteram, Natalie Lawson, Katherine Reynolds, Carl Fratter, Patricia Bignell, Anouk Groenheide, Dana Huskens, Bas De Laat, Jeremy A Pike, Natalie Poulter, Steven Thomas, Gillian LoweJonathan Lancashire, Paul Harrison, Neil Morgan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Scott syndrome is a mild platelet-type bleeding disorder, first described in 1979, with only 3 unrelated families identified through defective phosphatidylserine (PS) exposure and confirmed by sequencing. The syndrome is distinguished by impaired surface exposure of procoagulant PS on platelets after stimulation. To date, platelet function and thrombin generation in this condition has not been extensively characterised.

Objectives: Genetic and functional studies were undertaken in a consanguineous family with a history of excessive bleeding of unknown cause.

Patients/Methods: A targeted gene panel of known bleeding and platelet genes was used to identify possible genetic variants. Platelet phenotyping, flow adhesion, flow cytometry, whole blood and platelet-rich-plasma thrombin generation and specialised extracellular vesicle measurements were performed.

Results: We detected a novel homozygous frameshift variant, c.1943del (p.Arg648Hisfs*23), in ANO6 encoding Anoctamin 6, in a patient with a bleeding history, but interestingly with normal ANO6 expression. Phenotyping of the patient’s platelets confirmed the absence of PS expression and procoagulant activity, but also revealed other defects including reduced platelet δ granules, reduced ristocetin-mediated aggregation and secretion, and reduced P-selectin expression after stimulation. PS was absent on spread platelets and thrombi formed over collagen at 1500/s. Reduced thrombin generation was observed in PRP and confirmed in whole blood using a new thrombin generation assay.

Conclusion: We present a comprehensive report of a patient with Scott syndrome with a novel frameshift variant in AN06, which is associated with no platelet PS exposure and markedly reduced thrombin generation in whole blood, explaining the significant bleeding phenotype observed.

Original languageEnglish
JournalJournal of Thrombosis and Haemostasis
Early online date15 Mar 2024
DOIs
Publication statusE-pub ahead of print - 15 Mar 2024

Bibliographical note

Funding:
The work is supported by the British Heart Foundation (PG/13/36/30275; FS/15/18/31317; PG/16/103/32650; FS/18/11/33443 for NVM, AA/18/2/34218 for SJM, BHF PhD studentships FS/19/68/34583 for JP and FS/PhD/22/29245 for NJP). The National Institute of Health and Care Research (NIHR) Birmingham Biomedical Research Centre (NIHR203326) and the British Heart Foundation Accelerator (AA/18/2/34218) have supported the University of Birmingham Institute of Cardiovascular Sciences where this research is based. The opinions expressed in this paper are those of the authors and do not represent any of the listed organizations.

Keywords

  • Scott syndrome
  • ANO6
  • bleeding
  • thrombin generation
  • procoagulant platelets
  • extracellular vesicles

Fingerprint

Dive into the research topics of 'Comprehensive functional characterisation of a novel ANO6 variant in a new patient with Scott Syndrome'. Together they form a unique fingerprint.

Cite this